Xiaoyan Michelle Zhang - 10 Jan 2022 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role
Chief Scientific Officer
Signature
/s/ Douglas R. Carlson, as Attorney-in-Fact for Xiaoyan Michelle Zhang
Issuer symbol
IKNA
Transactions as of
10 Jan 2022
Net transactions value
-$9,854
Form type
4
Filing time
12 Jan 2022, 18:25:48 UTC
Previous filing
14 Dec 2021
Next filing
04 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IKNA Common Stock Options Exercise $77.26 +36 +0.08% $2.15 44,511 10 Jan 2022 Direct
transaction IKNA Common Stock Sale $432 -36 -0.08% $12.00 44,475 10 Jan 2022 Direct F1
transaction IKNA Common Stock Options Exercise $2,069 +964 +2.2% $2.15 45,439 11 Jan 2022 Direct
transaction IKNA Common Stock Sale $11,568 -964 -2.1% $12.00 44,475 11 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKNA Stock Option (Right to Buy) Options Exercise $0 -36 -0.14% $0.000000 25,437 10 Jan 2022 Common Stock 36 $2.15 Direct F2
transaction IKNA Stock Option (Right to Buy) Options Exercise $0 -964 -3.8% $0.000000 24,473 11 Jan 2022 Common Stock 964 $2.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021.
F2 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.